CTOs on the Move

Biotics Research Corporation

www.bioticsresearch.com

 
Biotics Research Corporation is a Rosenberg, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Naveos

NAVEOS® is the proven leader in maximizing the value of governmental program reimbursements for healthcare providers. Since 2005, our superior approach to data analytics has enabled healthcare providers to realize almost one billion dollars in additional DSH/340B reimbursement payments. NAVEOS® has developed a fully integrated DSH/340B software solution with a national eligibility verification network for both Medicare and Medicaid data. This system, which is the most robust in the industry, uses sophisticated algorithms to match eligibility data with patient data, applies the most up to date Federal and State regulatory parameters, then builds comprehensive deliverables for supporting DSH/340B filings. By leveraging our state-of-the-art technology and unsurpassed domain expertise, we generate best-in-class deliverables that yield impressive value and achieve a stellar (99.7%) audit acceptance rate.

Extend Fertility

Extend Fertility is the first service in the U.S. focused exclusively on women who want to proactively preserve their fertility options.

Direct Flow Medical

Founded in 2004, Direct Flow Medical®, Inc. is focused on developing novel transcatheter heart valve technologies that improve patient outcomes while reducing patient complications. The company is exploring application of its proprietary technology beyond the aortic valve, to the mitral valve and other valve anatomy. Headquartered in Santa Rosa, California, the company also has technology and manufacturing facilities in Lake Forest, California. The Direct Flow Medical TAVI system received the CE Mark in January 2013 and is currently available commercially in Europe. Company Culture: Direct Flow Medical, Inc. has a very unique corporate culture and has developed a set of principles that makes this a unique place to work. Our company is a community, and people feel best when they are proud of their community and know that it is accomplishing something worthwhile. Our employees are encouraged to get to know one another and to support one another in their achievements. We acknowledge and celebrate professional goals as well as personal milestones. The atmosphere at Direct Flow Medical, Inc. is one that supports both a sense of satisfaction from our work, and also a sense of companionship with our co-workers.

Mountain Laurel Medical Center

Mountain Laurel Medical Center is a community health center that provides primary health care, wellness promotion, and education to individuals in Garrett County and surrounding areas.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic